Search Results - "Amin, Neha P"

Immunotherapy, Radiotherapy, and Hyperthermia: A Combined Therapeutic Approach in Pancreatic Cancer Treatment by Mahmood, Javed, Shukla, Hem D, Soman, Sandrine, Samanta, Santanu, Singh, Prerna, Kamlapurkar, Shriya, Saeed, Ali, Amin, Neha P, Vujaskovic, Zeljko

“…Pancreatic cancer (PC) has the highest mortality rate amongst all other cancers in both men and women, with a one-year relative survival rate of 20%, and a…”
Get full text

Advances in proton therapy in lung cancer by Vyfhuis, Melissa A.L., Onyeuku, Nasarachi, Diwanji, Tejan, Mossahebi, Sina, Amin, Neha P., Badiyan, Shahed N., Mohindra, Pranshu, Simone, Charles B.

“…Lung cancer remains the leading cause of cancer deaths in the United States (US) and worldwide. Radiation therapy is a mainstay in the treatment of locally…”
Get full text

Systematic Review of the Cost Effectiveness of Radiation Therapy for Prostate Cancer from 2003 to 2013 by Amin, Neha P., Sher, David J., Konski, Andre A.

“…Background Prostate cancer remains a prevalent diagnosis with a spectrum of treatment choices that offer similar oncologic outcomes but differing side effect…”
Get full text

Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy by Amin, Neha P., MD, Zainib, Maliha, BS, Parker, Sean M., BS, Agarwal, Manuj, MD, Mattes, Malcolm D., MD

“…Abstract Purpose Radiation therapy (RT) and nivolumab are standard therapies for a wide range of advanced and metastatic cancers, yet little is known about the…”
Get full text

Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy? by Lamichhane, Purushottam, Amin, Neha P, Agarwal, Manuj, Lamichhane, Narottam

“…Checkpoint inhibition (CPI) has been a rare success story in the field of cancer immunotherapy. Knowledge gleaned from preclinical studies and patients that do…”
Get full text

Hyperthermia and Hyper-fractionated Radiation for a Cutaneous Squamous Cell Carcinoma Progressing on Standard Therapy: A Case Report by DeCesaris, Cristina, MD, Amin, Neha P., MD, Hundal, Jagdeep, MD, Vujaskovic, Zeljko, MD, PhD, Agarwal, Manuj, MD

Get full text

Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial by Fizazi, Karim, González Mella, Pablo, Castellano, Daniel, Minatta, Jose N., Rezazadeh Kalebasty, Arash, Shaffer, David, Vázquez Limón, Juan C., Sánchez López, Héctor M., Armstrong, Andrew J., Horvath, Lisa, Bastos, Diogo A., Amin, Neha P., Li, Jia, Unsal-Kacmaz, Keziban, Retz, Margitta, Saad, Fred, Petrylak, Daniel P., Pachynski, Russell K.

“…Docetaxel has immunostimulatory effects that may promote an immunoresponsive prostate tumour microenvironment, providing a rationale for combination with…”
Get full text

CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer by Jänne, Pasi A, Planchard, David, Kobayashi, Kunihiko, Cheng, Ying, Lee, Chee Khoon, Valdiviezo, Natalia, Laktionov, Konstantin, Yang, Tsung-Ying, Yu, Yan, Kato, Terufumi, Jiang, Liyan, Chewaskulyong, Busyamas, Lucien Geater, Sarayut, Maurel, Jean-Marc, Rojas, Carlos, Takahashi, Toshiaki, Havel, Libor, Shepherd, Frances A, Tanaka, Kentaro, Ghiorghiu, Dana, Amin, Neha P, Armenteros-Monterroso, Elena, Huang, Xiangning, Chaudhry, Ammar Ahmed, Yang, James Chih-Hsin

“…We report CNS efficacy of first-line osimertinib plus chemotherapy versus osimertinib monotherapy in patients with epidermal growth factor receptor ( )-mutated…”
Get full text

Effect of induction chemotherapy on estimated risk of radiation pneumonitis in bulky non–small cell lung cancer by Amin, Neha P., M.D, Miften, Moyed, Ph.D, Thornton, Dale, C.M.D, Ryan, Nicole, C.M.D, Kavanagh, Brian, M.D, Gaspar, Laurie E, M.D., M.B.A

“…Abstract Patients with bulky non–small cell lung cancer (NSCLC) may be at a high risk for radiation pneumonitis (RP) if treated with up-front concurrent…”
Get full text

Incidental Coronary Artery Calcium on Breast Radiation Therapy Planning Scans Identifies Patients for Cardiac Preventive Therapy by Amin, Neha P., Kim, Samuel M., Lasio, Giovanni, Zhou, Jinghao, Romar, Linda, Shipman, Kalin, Dukes, Kelly, Amin, Nivee P.

“…The presence of coronary artery calcium (CAC>0) is associated with increased cardiac-related mortality and is a common indication to initiate statin therapy to…”
Get full text

Cardiac Monitoring for Thoracic Radiation Therapy: Survey of Practice Patterns in the United States by Amin, Neha P., Desai, Nina, Kim, Samuel M., Agarwal, Manuj, Amin, Nivee P.

“…The American Society of Clinical Oncology (ASCO) 2017 guidelines on cardiac monitoring during cancer treatments identified patients receiving thoracic…”
Get full text

Concurrent Radiation and Immunotherapy: Survey of Practice Patterns in the United States by Amin, Neha P, Remick, Jill, Agarwal, Manuj, Desai, Nina A, Bergom, Carmen, Simone, 2nd, Charles B

“…The objective of this study was to report on US radiation oncologists' (ROs) practice patterns and perceptions of concurrent radiation (RT) and immunotherapy…”
Get full text

Serum microRNA guiding personalized radiation therapy in non-small cell lung cancer by Amin, Neha P, Mohindra, Pranshu, Jabbour, Salma K

Get full text

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial by Fizazi, Karim, Retz, Margitta, Petrylak, Daniel P, Goh, Jeffrey C, Perez-Gracia, Jose, Lacombe, Louis, Zschäbitz, Stefanie, Burotto, Mauricio, Mahammedi, Hakim, Gravis, Gwenaelle, Bastos, Diogo Assed, McCune, Steven L, Vázquez Limón, Juan Carlos, Kwan, Edmond M, Castellano, Daniel, Fléchon, Aude, Saad, Fred, Grimm, Marc-Oliver, Shaffer, David R, Armstrong, Andrew J, Bhagavatheeswaran, Prabhu, Amin, Neha P, Ünsal-Kaçmaz, Keziban, Wang, Xuya, Li, Jun, Loehr, Andrea, Pachynski, Russell K

“…BackgroundCheckMate 9KD (NCT03338790) is a non-randomized, multicohort, phase 2 trial of nivolumab plus other anticancer treatments for metastatic…”
Get full text

Helical Therapy is Safe for Lung Stereotactic Body Radiation Therapy Despite Limitations in Achieving Sharp Dose Gradients by Amin, Neha P., Nalichowski, Adrian, Campbell, Shauna, Hyder, Jal, Spink, Robyn, Konski, Andre A., Dominello, Michael

“…Purpose: We observed that many of our helical therapy lung stereotactic body radiation therapy plans did not meet the Radiation Therapy Oncology Group (RTOG)…”
Get full text

Acute pancreatitis: An unexpected toxicity when combining nivolumab and stereotactic body radiation therapy by Amin, Neha P., Agarwal, Manuj, Zainib, Maliha, Simone, Charles B.

Get full text

Impact of induction chemotherapy on estimated risk of radiation pneumonitis in small cell lung cancer by Amin, Neha P, Miften, Moyed, Kavanagh, Brian, Raben, David, Camidge, D Ross, Thornton, Dale, Rochford, Nicole, Gaspar, Laurie E

“…Induction chemotherapy in patients with bulky small cell lung cancer (SCLC) could lead to decreased tumor burden, smaller radiation fields, and less pulmonary…”
Get more information

Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial by Sharma, Padmanee, Krainer, Michael, Saad, Fred, Castellano, Daniel, Bedke, Jens, Kwiatkowski, Mariusz, Patnaik, Akash, Procopio, Giuseppe, Wiechno, Pawel, Kochuparambil, Samith Thomas, Thomas, Christian, Arranz Arija, Jose Angel, McCune, Steven L., Hansen, Steinbjorn, Daugaard, Gedske, Amin, Neha P., Wang, Yumeng, David, Justin M., Pachynski, Russell Kent

“…22 Background: In preliminary analyses from the randomized phase 2, open-label CheckMate 650 trial, nivolumab (NIVO) 1 mg/kg (N1) plus ipilimumab (IPI) 3 mg/kg…”
Get full text

CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC) by Pachynski, Russell Kent, Retz, Margitta, Goh, Jeffrey C., Burotto, Mauricio, Gravis, Gwenaelle, Castellano, Daniel, Flechon, Aude, Zschaebitz, Stefanie, Shaffer, David R., Vazquez Limon, Juan Carlos, Grimm, Marc-Oliver, McCune, Steven L., Amin, Neha P., Li, Jia, Wang, Xuya, Unsal-Kacmaz, Keziban, Saad, Fred, Petrylak, Daniel P., Fizazi, Karim

“…Abstract only 5044 Background: CheckMate 9KD is a phase 2 trial of NIVO (anti-PD-1) combined with either rucaparib, docetaxel, or enzalutamide for mCRPC. PARP…”
Get full text

CheckMate 9KD Arm B final analysis: Efficacy and safety of nivolumab plus docetaxel for chemotherapy-naïve metastatic castration-resistant prostate cancer by Fizazi, Karim, González Mella, Pablo, Castellano, Daniel, Minatta, Jose Nicolas, Rezazadeh, Arash, Shaffer, David R., Vazquez Limon, Juan Carlos, Sánchez López, Héctor Manuel, Armstrong, Andrew J., Horvath, Lisa, Dzik, Carlos, Amin, Neha P., Li, Jia, Unsal-Kacmaz, Keziban, Retz, Margitta, Saad, Fred, Petrylak, Daniel Peter, Pachynski, Russell Kent

“…Abstract only 12 Background: CheckMate 9KD (NCT03338790) is a phase 2 trial of nivolumab (NIVO; anti-PD-1) in combination with rucaparib, docetaxel (DOCE), or…”
Get full text